These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 18154127

  • 1. [Dicarbamin--an effective protector of myelodepression in combined treatment for Hodgkin's disease].
    Gershanovich ML, Filatova LV.
    Vopr Onkol; 2007; 53(5):589-95. PubMed ID: 18154127
    [Abstract] [Full Text] [Related]

  • 2. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, Russo D, Baccarani M.
    Tumori; 1994 Dec 31; 80(6):453-8. PubMed ID: 7534963
    [Abstract] [Full Text] [Related]

  • 3. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie.
    Lancet; 2015 Apr 11; 385(9976):1418-27. PubMed ID: 25539730
    [Abstract] [Full Text] [Related]

  • 4. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK, Link BK, Ritchie JM, Shannon M, Wooldridge JE.
    Leuk Lymphoma; 2006 Apr 11; 47(4):657-63. PubMed ID: 16690524
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul 11; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

  • 6. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 7. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
    Brusamolino E, Lunghi F, Orlandi E, Astori C, Passamonti F, Baraté C, Pagnucco G, Baio A, Franchini P, Lazzarino M, Bernasconi C.
    Haematologica; 2000 Oct 20; 85(10):1032-9. PubMed ID: 11025593
    [Abstract] [Full Text] [Related]

  • 8. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M.
    J Clin Oncol; 1998 Dec 20; 16(12):3810-21. PubMed ID: 9850026
    [Abstract] [Full Text] [Related]

  • 9. [The whole dose at once?].
    Rodríguez García J, Ramos Ortega FJ, Sandoval Guerra V, García Sanz R.
    Sangre (Barc); 1996 Jun 20; 41(3):259. PubMed ID: 8755216
    [No Abstract] [Full Text] [Related]

  • 10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.
    Ann Hematol; 2016 Apr 20; 95(5):809-16. PubMed ID: 26878861
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study.
    Minuk LA, Monkman K, Chin-Yee IH, Lazo-Langner A, Bhagirath V, Chin-Yee BH, Mangel JE.
    Leuk Lymphoma; 2012 Jan 20; 53(1):57-63. PubMed ID: 21740297
    [Abstract] [Full Text] [Related]

  • 12. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease.
    Clarke K, Grigg A.
    Leuk Lymphoma; 1995 Nov 20; 19(5-6):521-2. PubMed ID: 8590858
    [No Abstract] [Full Text] [Related]

  • 13. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA.
    J Clin Oncol; 2004 Jan 01; 22(1):62-8. PubMed ID: 14657226
    [Abstract] [Full Text] [Related]

  • 14. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.
    N Engl J Med; 2010 Aug 12; 363(7):640-52. PubMed ID: 20818855
    [Abstract] [Full Text] [Related]

  • 15. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
    Cullen MH, Stuart NS, Woodroffe C, Murphy A, Fletcher J, Blackledge GR, Child JA, Grieve RJ, Jones EL.
    J Clin Oncol; 1994 Apr 12; 12(4):779-87. PubMed ID: 7512132
    [Abstract] [Full Text] [Related]

  • 16. Super-acute onset of tumor lysis syndrome accompanied by hypercytokinemia during treatment of Hodgkin's lymphoma with ABVD chemotherapy.
    Suzuki T, Takeuchi M, Saeki H, Yamazaki S, Koga H, Abe D, Nishimura M, Nakaseko C, Nakasa H, Nakamura H, Ariyoshi N, Kitada M.
    Clin Ther; 2010 Mar 12; 32(3):527-31. PubMed ID: 20399989
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
    Merdin A, Çakar MK, Dal MS, Mert D, Yıldız J, Başçı S, Bakırtaş M, Darçın T, Şahin D, Ulu BU, Yiğenoğlu TN, Batgi H, Tetik A, İskender D, Altuntaş F.
    J Oncol Pharm Pract; 2020 Jun 12; 26(4):929-932. PubMed ID: 31822199
    [Abstract] [Full Text] [Related]

  • 18. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V.
    J Clin Oncol; 2002 Jan 15; 20(2):476-84. PubMed ID: 11786577
    [Abstract] [Full Text] [Related]

  • 19. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B.
    J Clin Oncol; 1997 Apr 15; 15(4):1638-45. PubMed ID: 9193364
    [Abstract] [Full Text] [Related]

  • 20. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM.
    J Clin Oncol; 1998 Jan 15; 16(1):19-26. PubMed ID: 9440718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.